/C O R R E C T I O N -- Corautus Genetics Inc./ In the news release, Corautus Genetics Inc. Announces Publication of Positive Gene Therapy Trial Results in Patients with Severe Angina, issued earlier today by Corautus Genetics Inc. (NASDAQ:VEGF) over PR Newswire, we are advised by a representative of the company that the seventh paragraph, second sentence should read "At the most recent follow-up, no patients had Class IV angina, and only three (11.5%) had Class III angina, while the remaining had Class I or II angina" rather than "and only three (11.5%) had Class II angina" as originally issued inadvertently. PRNewswire-FirstCall -- March 8 DATASOURCE: Corautus Genetics Inc.

Copyright